Atrial Fibrillation Clinical Trial Landscape
Data updated: May 20, 2026
479 clinical trials tracked since 2008
Atrial Fibrillation is being studied across 479 clinical trials registered since 2008, with 117 programs currently active. The competitive pipeline includes 36 active Phase 3 trials, 23 active Phase 2 trials, and 8 active Phase 1 trials. Top industry sponsors include Anthos Therapeutics, Inc., Regeneron, Novartis.
117 active
/
479 total (since 2008)
8
Phase 1 Active
36 total
23
Phase 2 Active
100 total
36
Phase 3 Active
143 total
59
Phase 4 Active
221 total
Top Industry Sponsors
Sorted by active Active Done Failed
Anthos Therapeutics, Inc. 2 1 0
Regeneron 2 0 0
Novartis 1 0 2
Acesion Pharma 1 1 0
HUYABIO International, LLC. 1 1 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT03907046 RECRUITING
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Yale University n=700
NCT05757869 ACTIVE NOT RECRUITING
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Janssen Research & Development, LLC n=20,284
NCT07430956 RECRUITING
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Regeneron Pharmaceuticals n=2,628
NCT05836987 RECRUITING
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Johns Hopkins University n=5,350
NCT03243175 RECRUITING
Avoiding Anticoagulation After IntraCerebral Haemorrhage
University Hospital, Lille n=300
+ 138 more Phase 3 trials — see full database below
Atrial Fibrillation — Trials Started by Year (last 10 years)
2016 22
2017 23
2018 23
2019 28
2020 18
2021 20
2022 19
2023 24
2024 25
2025 25
2026 16
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Anthos Therapeutics, Inc. 3
Regeneron 2
Novartis 3
Acesion Pharma 2
HUYABIO International, LLC. 2
Johnson & Johnson 1
Les Laboratoires des Médicaments Stériles 1
Helios Cardio Inc. 1
HK inno.N Corporation 1
Biosense Webster, Inc. 15
Active Trials by Phase
Phase 1 8
Phase 2 23
Phase 3 36
Phase 4 59
Enrollment Size Distribution
1-50 99
51-200 187
201-500 86
501-1k 28
1k+ 54
All Industry Sponsors
Sorted by active Active Done Failed
Anthos Therapeutics, Inc. 2 1 0
Regeneron 2 0 0
Novartis 1 0 2
Acesion Pharma 1 1 0
HUYABIO International, LLC. 1 1 0
Johnson & Johnson 1 0 0
Les Laboratoires des Médicaments Stériles 1 0 0
Helios Cardio Inc. 1 0 0
HK inno.N Corporation 1 0 0
Biosense Webster, Inc. 0 10 5
Bayer 0 7 1
Sanofi 0 4 4
Bristol-Myers Squibb 0 5 2
Boehringer Ingelheim 0 5 0
CardioFocus 0 4 1
NCT03907046 RECRUITING
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Yale University n=700
NCT05757869 ACTIVE NOT RECRUITING
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Janssen Research & Development, LLC n=20,284
NCT07560644 NOT YET RECRUITING
Restoring Sinus Rhythm Using Dual-Shock Technique in Patients With Atrial Fibrillation
Martín Negreira Caamaño n=177
NCT07430956 RECRUITING
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Regeneron Pharmaceuticals n=2,628
NCT05836987 RECRUITING
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Johns Hopkins University n=5,350
NCT03243175 RECRUITING
Avoiding Anticoagulation After IntraCerebral Haemorrhage
University Hospital, Lille n=300
NCT05174052 RECRUITING
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
University of Oklahoma n=28
NCT05712200 RECRUITING
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Anthos Therapeutics, Inc. n=1,900
NCT07434661 NOT YET RECRUITING
Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR
Meshalkin Research Institute of Pathology of Circulation n=120
NCT04045665 RECRUITING
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Icahn School of Medicine at Mount Sinai n=3,200
NCT06716021 NOT YET RECRUITING
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
Milestone Pharmaceuticals Inc. n=750
NCT06722196 RECRUITING
BiodEgradable Soaked Amiodarone paTch Use for the Prevention of Atrial Fibrillation After Cardiac Surgery
Jilin Heart Hospital n=500
NCT06499857 RECRUITING
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
University of Chicago n=200
NCT06376916 RECRUITING
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Wake Forest University Health Sciences n=153
NCT07187570 RECRUITING
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
Region Stockholm n=1,600
NCT05841056 RECRUITING
Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial
Population Health Research Institute n=400
NCT05549752 RECRUITING
Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia
Hippocration General Hospital n=80
NCT06789588 ENROLLING BY INVITATION
Protocol for Improvement of Therapy With Warfarin
University of Pernambuco n=700
NCT05890664 RECRUITING
Colchicine After Electrocardioversion for Atrial Fibrillation
University Hospital, Basel, Switzerland n=416
NCT02750319 ACTIVE NOT RECRUITING
Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery
Memorial Sloan Kettering Cancer Center n=184
NCT05357690 RECRUITING
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
Mayo Clinic n=220
NCT05852704 RECRUITING
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
Region Örebro County n=800
NCT06900725 NOT YET RECRUITING
Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke
National Taiwan University Hospital n=300
NCT06276127 NOT YET RECRUITING
Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate.
Oman Medical Speciality Board n=60
NCT05717725 RECRUITING
Pulsed-field Ablation Vs. Sham Ablation to Treat AF
Charles University, Czech Republic n=60
NCT06715449 RECRUITING
EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source
University of East Anglia n=100
NCT05679024 RECRUITING
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Region Stockholm n=1,400
NCT06045858 NOT YET RECRUITING
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
University Hospital, Caen n=178
NCT05169866 RECRUITING
Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery
Beijing Anzhen Hospital n=274
NCT04748991 NOT YET RECRUITING
Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients
University of Calgary n=50
NCT05928728 RECRUITING
The COLchicine and Atrial FIBrillation Trial
Herlev and Gentofte Hospital n=500
NCT06204640 NOT YET RECRUITING
SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
University Hospital, Caen n=580
NCT05293080 RECRUITING
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
Universitätsklinikum Hamburg-Eppendorf n=1,746
NCT06111443 ACTIVE NOT RECRUITING
Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation
Chang Gung Memorial Hospital n=196
NCT05939076 NOT YET RECRUITING
First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation
Region Örebro County n=220
NCT03331484 COMPLETED
The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
Ottawa Heart Institute Research Corporation n=40
NCT04607122 COMPLETED
Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery
CMC Ambroise Paré n=400
NCT03683030 COMPLETED
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
Biosense Webster, Inc. n=397
NCT01898221 COMPLETED
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
The Methodist Hospital Research Institute n=343
NCT06675500 COMPLETED
Evaluation of the Role of Magnesium in Prevention of AF Post Cardiac Surgery
Ain Shams University n=130
NCT04870424 COMPLETED
Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Insel Gruppe AG, University Hospital Bern n=120
NCT02387229 TERMINATED
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
Montreal Heart Institute n=1,238
NCT01824394 TERMINATED
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
Biosense Webster, Inc. n=481
NCT01385202 COMPLETED
THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
Biosense Webster, Inc. n=172
NCT00721149 TERMINATED
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study
Biosense Webster, Inc. n=10
NCT06013345 COMPLETED
COnventional Vs. Optimised PERiprocedural Analgosedation Vs. Total IntraVEnous Anaesthesia for Pulsed-Field Ablation (COOPERATIVE-PFA)
Charles University, Czech Republic n=127
NCT03996772 COMPLETED
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
Imperial College London n=319
NCT05643573 TERMINATED
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Bayer n=14,830
NCT06114719 COMPLETED
Silymarin for the Prevention of Atrial Fibrillation After Cardiac Surgery
University of Novi Sad n=160
NCT01924065 COMPLETED
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Suleyman Demirel University n=112
NCT04037397 COMPLETED
First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)
University of Pennsylvania n=25
NCT04160117 COMPLETED
Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)
Population Health Research Institute n=202
NCT05669417 TERMINATED
Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.
HagaZiekenhuis n=265
NCT04042727 TERMINATED
Controlling Rapid Atrial Fibrillation With Dexmedetomidine
Stony Brook University n=13
NCT04885634 WITHDRAWN
Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
Axel Brandes
NCT05039359 TERMINATED
Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation
InCarda Therapeutics, Inc. n=54
NCT03702582 COMPLETED
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
Massachusetts General Hospital n=100
NCT03310125 COMPLETED
Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)
Population Health Research Institute n=3,209
NCT03718273 COMPLETED
IvaBRAdine blocK of Funny Current for Heart Rate Control in permanEnt Atrial Fibrillation. (BRAKE-AF Study).
Adolfo Fontenla n=68
NCT02933697 COMPLETED
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
Atrial Fibrillation Network n=108
NCT03807037 COMPLETED
Safety and Efficacy of Tocotrienols in Post-CABG Atrial Fibrillation
Monash University Malaysia n=250
NCT03181386 COMPLETED
Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants
University of Sao Paulo General Hospital n=60
NCT03153150 COMPLETED
Start or STop Anticoagulants Randomised Trial (SoSTART)
University of Edinburgh n=203
NCT03682393 WITHDRAWN
Post-operative Corticosteroid Treatment After Mitral Valve Surgery
Kuopio University Hospital
NCT02943785 COMPLETED
Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
Daiichi Sankyo n=1,426
NCT01235130 COMPLETED
Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation
Montreal Heart Institute n=337
NCT03273322 COMPLETED
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
Assistance Publique - Hôpitaux de Paris n=105
NCT02283294 COMPLETED
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
University of South Florida n=91
NCT01985425 COMPLETED
Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study
Population Health Research Institute n=100
NCT03926156 TERMINATED
RIvoraxaban in Mitral Stenosis
Rajaie Cardiovascular Medical and Research Center n=40
NCT03839355 TERMINATED
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
Mayo Clinic n=34
NCT02282098 COMPLETED
Colchicine in Atrial Fibrillation to Prevent Stroke
Population Health Research Institute n=80
NCT02866175 COMPLETED
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company n=1,506
NCT03015831 TERMINATED
Effect of Low Dose ColchiciNe on the InciDence of POAF
Jordan Collaborating Cardiology Group n=254
NCT02942576 COMPLETED
Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company n=632
NCT01873352 COMPLETED
Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation
Meshalkin Research Institute of Pathology of Circulation n=302
NCT03162120 WITHDRAWN
Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
Elpen Pharmaceutical Co. Inc.
NCT02072434 COMPLETED
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
Daiichi Sankyo n=2,199
NCT02132767 COMPLETED
Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Icahn School of Medicine at Mount Sinai n=523
NCT00781391 COMPLETED
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
Daiichi Sankyo n=21,105
NCT01857622 COMPLETED
Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
Daiichi Sankyo Co., Ltd. n=93
NCT02202967 COMPLETED
Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs
NHS Greater Glasgow and Clyde n=104
NCT02164864 COMPLETED
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
Boehringer Ingelheim n=2,725
NCT01182441 COMPLETED
Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Boston Scientific Corporation n=407
NCT01639495 COMPLETED
THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS
Biosense Webster, Inc. n=148
NCT00953212 COMPLETED
Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery
MaineHealth n=304
NCT02533843 COMPLETED
Outcome of Different Ablation Strategies In Persistent and Long-Standing Persistent Atrial Fibrillation
Texas Cardiac Arrhythmia Research Foundation n=120
NCT00965874 COMPLETED
Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation
University of Monastir n=450
NCT02582190 WITHDRAWN
COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF
Elpen Pharmaceutical Co. Inc.
NCT01830543 COMPLETED
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Janssen Scientific Affairs, LLC n=2,124
NCT02177266 TERMINATED
Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation
Mayo Clinic n=2
NCT01349491 TERMINATED
Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion
University of Oklahoma n=10
NCT01867060 COMPLETED
Using a Personal Heart Rhythm Monitor to Diagnose Paroxsymal Atrial Fibrillation in the Community
University of Surrey n=194
NCT01917981 WITHDRAWN
Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation
University of Surrey
NCT01932112 COMPLETED
Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
Yong Seog Oh n=378
NCT01362738 COMPLETED
Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcome in Patients With Persistent or Long-standing Persistent Atrial Fibrillation Undergoing Catheter Ablation
Texas Cardiac Arrhythmia Research Foundation n=156
NCT00970489 COMPLETED
Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation
Brigham and Women's Hospital n=1,516
NCT01999829 COMPLETED
Prevention of Atrial Fibrillation Following Valvular Replacement With Cardiopulmonary Bypass: a Prospective, Randomized Clinical Study Comparing Oral Caffeine With Placebo
Assistance Publique Hopitaux De Marseille n=110
NCT01729871 COMPLETED
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
Janssen Scientific Affairs, LLC n=253
NCT03017001 COMPLETED
Preoperative Carbohydrate Load and Intraoperative w3-PUFA in CAGB Surgery
Federal University of Mato Grosso n=60
NCT02071680 COMPLETED
Autonomic Innervation and MIBG Imaging
Ottawa Heart Institute Research Corporation n=5
NCT01391091 COMPLETED
Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine
Texas Cardiac Arrhythmia Research Foundation n=173
NCT02454283 TERMINATED
Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Laguna Pharmaceuticals, Inc. n=41
NCT01456000 COMPLETED
HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)
CardioFocus n=405
NCT00958165 COMPLETED
Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic AF
CardioFocus n=81
NCT02325778 COMPLETED
Comparison of CTI Ablation Prior to or After LA Ablation for AF
NYU Langone Health n=132
NCT01839357 COMPLETED
Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
Bayer n=60
NCT02270151 COMPLETED
Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick
UMC Utrecht n=16,000
NCT00839657 COMPLETED
Clarification of Optimal Anticoagulation Through Genetics
National Heart, Lung, and Blood Institute (NHLBI) n=1,015
NCT00786474 COMPLETED
Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
Duke University n=1,884
NCT01182376 COMPLETED
SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI
University of Utah n=33
NCT01174160 COMPLETED
A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)
Advanz Pharma n=123
NCT02317068 COMPLETED
Increasing Atrial Base Rate Pacing to Reduce Atrial Fibrillation
Urmia University of Medical Sciences n=200
NCT01107730 COMPLETED
Vitamin C for Prophylaxis of Post-operative Atrial Fibrillation in On-pump Cardiac Surgery Procedures
Attikon Hospital n=33
NCT00908700 COMPLETED
Left Atrial Appendage Occlusion Study II
Population Health Research Institute n=51
NCT00736294 TERMINATED
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Centre Hospitalier Universitaire de Saint Etienne n=198
NCT01656772 COMPLETED
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Stereotaxis n=120
NCT01994070 COMPLETED
Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation
University of British Columbia n=86
NCT01580683 WITHDRAWN
Vitamin C and Atrial Fibrillation After Cardiac Surgery
Regional Hospital of Scranton
NCT01674647 COMPLETED
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Bayer n=1,504
NCT01175330 TERMINATED
Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting
Meshalkin Research Institute of Pathology of Circulation n=39
NCT01570530 TERMINATED
Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery
Fundación General Universidad de Valladolid n=90
NCT01173809 COMPLETED
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation
Texas Cardiac Arrhythmia Research Foundation n=176
NCT01281787 COMPLETED
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
European Institute of Oncology n=320
NCT00808067 COMPLETED
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
Boehringer Ingelheim n=5,897
NCT01654042 WITHDRAWN
Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II
McMaster University
NCT00989001 TERMINATED
A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)
Advanz Pharma n=217
NCT00873067 COMPLETED
Benefit of Complex Fractionated Atrial Electrograms Elimination in Atrial Fibrillation Ablation
Hospital Clinic of Barcelona n=142
NCT01203241 COMPLETED
Benefit of Left Atrial Roof Ablation in Paroxysmal Atrial Fibrillation
Hospital Clinic of Barcelona n=120
NCT00821353 COMPLETED
Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
National Institute of Cardiology, Warsaw, Poland n=90
NCT01151137 TERMINATED
Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy
Sanofi n=3,236
NCT00741611 TERMINATED
Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation
C. R. Bard n=44
NCT01178034 COMPLETED
Early Identification of Warfarin Maintenance Dosage
University of Padova n=180
NCT01173796 COMPLETED
Ablation of Perimitral Flutter Following Catheter Ablation of Atrial Fibrillation: Impact on Outcomes
Texas Cardiac Arrhythmia Research Foundation n=44
NCT01611701 COMPLETED
Cryoballoon Ablation of Pulmonary Veins After Failed RF Ablation in Patients With Paroxysmal AF
Meshalkin Research Institute of Pathology of Circulation n=80
NCT01164319 COMPLETED
"UNMASKING Study" For Atrial Fibrillation Recurrences Typing in Early Postoperative Period
Meshalkin Research Institute of Pathology of Circulation n=150
NCT00668759 COMPLETED
A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation
Advanz Pharma n=254
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only